BioSpace News Archive

Guidelines provide recommendations on the diagnosis and management of glaucoma within the EU Nine MicroPulse TLT studies presented at the annual EGS meeting supporting its safety, effectiveness, and versatility in the treatment of glaucoma

Amgen (NASDAQ:AMGN) and Medicines Development for Global Health (MDGH), a non-profit biopharmaceutical company, today announced that the companies have entered into a license agreement for AMG 634, a phosphodiesterase type 4 (PDE4) inhibitor being investigated for the treatment of tuberculosis (TB

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company’s President and Chief Executive Officer, is scheduled to present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 , at 10:00 AM ET . A live webcast of the presentation will be posted under t

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs ™ ), today announced that Sarah Boyce , President and Chief Executive Officer, is scheduled to present at the 39 th Annual J.P. Morgan Healthcare Confer

Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, announced today that John Schroer, the Company’s Chief Financial Officer (CFO), is departing the Company for personal reasons. Mr. Schroer’s departure will be effective by year-end 2020. Robert Prentiss, Translate Bio’s Vice Presid

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the 39th Annual J.P. Morgan Healthcare Conference via webcast. BD’s CEO and president is scheduled to present on Tuesday, January 12, 2021 at 7:30 a.m. Eastern Time.

Hyundai Bioscience (KOSDAQ symbol: 048410) announced on the 23rd, December 2020, that CNPharm, its major shareholding bio tech company, has succeeded in developing ‘Poly-COV01,’ an injection drug for the potential treatment of patients with severe cases of COVID-19

The new MRI on wheels is cleared for brain imaging and can be brought directly to the patient, making care easier and more convenient for a wide variety of patients, including children, emergency patients and patients with coronavirus.

908 Devices Inc., a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the closing of its upsized initial public offering of shares of its common stock, with 7,475,000 shares offered and sold by the Company at a public offering price of $20.00 per share, which includes the full exercise of the underwriters’ option to purchase an additional 975,000 shares of comm

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that an Emergency Use Authorization (EUA) Application has been submitted to the US Food and Drug Administration for its COVI-STIX rapid diagnostic test for the detection of the SARS-CoV-2 virus nucleocapsid antigen in nasal samples of patients.